Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy

Personalized medicine in treating pancreatic ductal adenocarcinoma (PDAC) is still in its infancy, albeit PDAC-related deaths are projected to rise over the next decade. Only recently, maintenance therapy with the PARP inhibitor olaparib showed improved progression-free survival in germline BRCA1/2-...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cells
Prif Awduron: Roger, Elodie, Gout, Johann, Arnold, Frank, Beutel, Alica K., Müller, Martin, Abaei, Alireza, Barth, Thomas F. E., Rasche, Volker, Seufferlein, Thomas, Perkhofer, Lukas, Kleger, Alexander
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563330/
https://ncbi.nlm.nih.gov/pubmed/32948057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9092110
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg